Focus

June 6, 2008

Pathology
Pre-eclampsia Linked to Lack of Protein that Dampens Vessel Growth

NIH Funding
Grant Will Galvanize Translational Science

Strategic Planning
Reporting Continues on Biomedical Research Directions

Immunology
Findings Blaze Novel Cell Death Pathway

Oncology
Drug Used for One Leukemia KOs Cancer Stem Cells in Another

Infectious Disease
Controlling HIV Demands Novel Vaccine Approach

Education
The Long and Short of Learning

Health Care Policy
Health Care Policy Department Turns 20, Continues to Repair the System

Minority Health Policy
Minority Health Policy as Avenue for Change

New Books
The Spring Bookshelf

Smoking Is Addictive, But Quitting Is Contagious

Professor Appointed Academic And Clinical Dean

Education and Medicine Linked in Academy Chair

Four Faculty Members Become Howard Hughes Investigators

Surgery Heads Recognized for Advancement of Women

Scientist to Lead Oral Medicine

HST Society Renamed for Founding Director

Diabetes Award Honors Medical Dean Flier

Exceptional Teachers Honored

New Dean Named for Research Integrity

Field of Rheumatology Moves Ahead With Professorship

Social Medicine Goes Global

 

Keeping Patients First

Front Page

IMMUNOLOGY

Findings Blaze Novel Cell Death Pathway

Granzyme Action Opens Approach to Autoimmunity, Cancer

The elucidation of the cell death pathway triggered by the protein granzyme A (GzmA) has prompted investigators to re-evaluate their concept of programmed cell death. It is no longer considered exclusively mediated by caspases, sometimes thought of as executioner enzymes, which can be evaded by tumor cells. Instead, GzmA activates a death cascade that has many of the hallmarks of apoptosis but without engaging the caspases.

Denis Martinvalet and Judy Lieberman
Graham Ramsay

Denis Martinvalet and Judy Lieberman have been working to elucidate the granzyme A–mediated apoptotic pathway.



Granzyme proteases are deployed by cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells to destroy tumors and cells infected with viruses. They are released from cytotoxic granules together with perforin, which facilitates delivery of granzymes into target cells, where they activate apoptosis. GzmA is the most abundant of the five known human granzymes, but its mechanism of action has only recently been described.

The lab of Judy Lieberman, HMS professor of pediatrics at the Immune Disease Institute, has been unraveling the GzmA cell death machinery, identifying some of its molecular targets. The researchers have now uncovered a new GzmA-activated mitochondrial cell death pathway, the first stage in triggering subsequent DNA damage and cell death. Mitochondrial damage is triggered when GzmA surprisingly traffics across two membranes into the heart of the mitochondrion, the mitochondrial matrix. As described in the May 16 Cell, they used a proteomics approach to identify potential GzmA mitochondrial cleavage substrates. Of the 307 mitochondrial proteins they resolved, NDUFS3, a component of the mitochondrial electron transport chain complex I, proved to be the critical GzmA target.

A better understanding of the granzyme’s basis of action may offer novel therapeutic targets for treatment of autoimmune diseases and alternate therapies for killing tumor cells that have found ways to escape cell death.

Assault by Granzyme A
Mitochondrial dysfunction is a hallmark of apoptosis. In the caspase pathway, mitochondrial outer membrane permeabilization permits the release of pro-apoptotic factors like cytochrome c (cyt c) that activate the caspases. Membrane permeabilization was thought to be the critical apoptotic event until a study published by the Lieberman lab three years ago. Denis Martinvalet, a research fellow in the Lieberman lab, noticed that GzmA caused generation of reactive oxygen species (ROS) and the destruction of the mitochondrial membrane potential, but did not disrupt the outer mitochondrial membrane or activate caspases. Moreover, he found that ROS generation was critical for both GzmA and caspase-dependent cell death, since treating target cells with superoxide scavengers blocked both pathways completely.

“Most apoptosis research has been focused on the caspases, the pathway that is important in development and remodeling. For a long time people couldn’t believe that we had another pathway of apoptosis,” said Lieberman.

“Most apoptosis research has been focused on the caspases, the pathway that is important in development and remodeling. For a long time people couldn’t believe that we had another pathway of apoptosis.”

Part of what makes the GzmA cell death pathway unique is that DNA damage is caused by single-stranded cuts, resulting in fragments that are much larger than the double-strand breaks found in the classical caspase-mediated apoptotic pathways. These DNA fragments are too large to be released from the nucleus until hours later, causing GzmA to have been incorrectly tied to a slow, non-apoptotic death.
ROS generation by GzmA in the mitochondria is an essential first step for this caspase-independent apoptotic pathway, triggering the nuclear translocation of the GzmA-activated DNases that destroy DNA. These DNases are inhibited if superoxide is scavenged, GzmA is blocked from entering mitochondria, or a GzmA-noncleavable variant of its mitochondrial substrate NDUFS3 is expressed in a target cell. While the researchers previously showed that GzmA acted directly on mitochondria, their current study unveils the mitochondrial substrate NDUFS3.

Reactive Oxygen
The mitochondrial electron transport chain consists of a series of metalloproteins, complexes I–V, bound to the mitochondrial inner membrane. It behaves like a molecular wire that transfers electrons to O2. During transport, energy is pumped from electrons and transiently stored as a proton gradient across the inner membrane, which is used to produce ATP. GzmA cleavage of NDUFS3 in electron transport complex I interferes with the start of electron transfer. As a consequence, the misdirected electrons generate ROS, the mitochondrial transmembrane potential dissipates, and ATP generation is compromised.

Immunoelectron microscopy confirmed GzmA was internalized into mitochondria, raising the question of how GzmA gets inside. GzmA neither contains a mitochondrial import sequence, nor disrupts the mitochondrial membrane; however, it was found to bind with high affinity to heat shock proteins that chaperone their cargo to specialized transport machinery embedded in the mitochondrial double membranes.

Another program for cell death. The death-inducing protease granzyme A (GzmA) enters mitochondria to attack electron transport. GzmA, introduced into the cytosol of target cells by perforin, enters the mitochondrial matrix, most likely via the TOM/TIM twin translocases. Within the matrix, GzmA cleaves a key electron relay protein, NDUFS3, in electron transport complex I to interfere at the start of electron transfer. The misdirected electrons generate ROS, the mitochondrial transmembrane potential dissipates, and ATP generation is compromised. Unlike other apoptotic pathways, the mitochondrial outer membrane is not disrupted and proapoptotic factors like cytochrome c in the intermembrane space are not released.



The NDUFS3 cleavage site was identified by mass spectrometry analysis and was confirmed by expressing the cleavage site mutant in target cells, where it prevented GzmA-mediated ROS generation and cell death, underscoring the importance of ROS in GzmA-mediated cell death.

In contrast to what scientists used to believe about free-radical production during cell death, “this study confirms the fact that there is a pathway leading to free radical production. ROS are not byproducts, they are produced for a purpose. There seems to be a really organized way that GzmA reaches its mitochondrial target that is focused on producing free radicals,” said Martinvalet.

R. Chris Bleackley, professor of biochemistry at the University of Alberta, who has made significant advances in GzmB-mediated apoptosis, which activates both caspase-dependent and caspase-independent apoptosis, believes that a better understanding of the molecular basis of the action of GzmA and GzmB will be helpful in determining how to downregulate them when they go awry in autoimmune disease. Moreover, caspase-independent pathways are important for killing tumor cells because many tumor cells and some viruses are resistant to caspase cell death pathways. “In these particular cases, Judy’s new pathway is incredibly important,” said Bleackley, who was not an author on the paper. “That’s the way GzmA will really come into prominence.”

 


top